The global coronary stent market size is expected to reach USD 12,248.80 million by 2032, expected to grow at a CAGR of 4.40% during the forecast period.
The Coronary Stent Market is a rapidly growing segment of the medical device industry, driven by the increasing prevalence of cardiovascular diseases (CVDs), advancements in stent technology, and rising healthcare investments. Coronary stents are small, expandable mesh tubes inserted into coronary arteries to restore and maintain blood flow. These devices are essential in treating coronary artery diseases (CADs) caused by plaque buildup, which restricts blood flow to the heart.
Market Growth Drivers
- Rising Cardiovascular Disease Burden: The increasing prevalence of CADs, coupled with sedentary lifestyles, unhealthy diets, and obesity, drives the need for coronary stents.
- Technological Advancements: Innovations in stent materials, coatings, and delivery systems have improved patient outcomes and reduced complications like restenosis.
- Growing Geriatric Population: Older individuals are more susceptible to CVDs, leading to an increased demand for coronary interventions.
Some of the major players operating in the global market include:
- Abbott Laboratories
- B. Braun Melsungen AG
- Biosensors International Group (acquired by Blue Sail Medical Co., Ltd)
- Biotronik SE & Co.KG
- Boston Scientific Corporation
- C. R. Bard, Inc.
- Cook Medicals
- Lepu Medicals
- Liaoning Biomedical Materials
- Medtronic Plc
- Meril Life Sciences
Download Free Sample PDF Copy of the Report:
https://www.polarismarketresearch.com/industry-analysis/coronary-stent-market/request-for-sample
Key Trends
- Next-Generation Stents: The development of bioresorbable stents and polymer-free drug-eluting stents aims to address limitations like late thrombosis and biocompatibility issues.
- Technological Integration: Advancements in imaging systems, such as Optical Coherence Tomography (OCT), are improving stent placement accuracy.
- Expansion in Emerging Markets: Developing countries in Asia-Pacific, Latin America, and the Middle East are witnessing increased adoption due to improving healthcare infrastructure.
Recent Developments
- In April 2021, Abbott unveiled the European launch of the Ultreon 1.0 Software, a coronary imaging platform powered by artificial intelligence (AI). This innovative software is designed to enhance the detection of calcium-based blockages and accurately measure vessel diameter during coronary stenting procedures.
- In February 2021, The Cardiovascular Systems Inc. announced a partnership with Chansu Vascular Technologies, LLC. This collaboration aims to develop drug-coated balloons for peripheral and coronary applications, specifically in conjunction with drug-eluting stents. This strategic partnership aims to leverage the expertise and resources of both companies to advance the field of interventional cardiology and enhance treatment options for patients requiring drug-eluting stents.
- In May 2022, Medtronic plc obtained approval from the FDA for its Onyx Frontier drug-eluting stent. The Onyx Frontier stent features an advanced delivery system designed to improve its deliverability and enhance acute performance during stent placement procedures. This approval by the FDA highlights the safety and efficacy of the Onyx Frontier stent, further solidifying Medtronic’s commitment to providing innovative solutions for cardiovascular interventions.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
Coronary Stent, Product Outlook (Revenue – USD Million, 2019 – 2032)
- Drug Eluting Stents
- Biodegradable
- Non-Biodegradable
- Bioresorbable Vascular Scaffold Stents
- Bare Metal Stents
- Covered Stents
- Others
Coronary Stent, Metal Outlook (Revenue – USD Million, 2019 – 2032)
- Cobalt Chromium
- Platinum Chromium
- Nickel Titanium
- Stainless Steel
Coronary Stent, Biomaterial Outlook (Revenue – USD Million, 2019 – 2032)
- Metallic biomaterials
- Polymers biomaterials
- Natural biomaterials
Coronary Stent, End-Use Outlook (Revenue – USD Million, 2019 – 2032)
- Hospitals
- Ambulatory Surgical Centers
- Cardiology Centers
- Specialty Clinics
- Others
The Coronary Stent Market is poised for sustained growth, fueled by technological advancements, increasing prevalence of cardiovascular diseases, and expanding healthcare access globally. As manufacturers innovate to address current limitations and cater to diverse patient needs, the market is set to play a crucial role in the future of interventional cardiology.
More Trending Latest Reports By Polaris Market Research: